Joint EANM-SNMMI guideline on the role of 2-[18F]FDG PET/CT in no special type breast cancer (endorsed by the ACR, ESSO, ESTRO, EUSOBI/ESR, and EUSOMA)

被引：19
作者：
Vaz, Sofia C. [1 ,2 ]
Woll, John Patrick Pilkington [3 ]
Cardoso, Fatima [4 ]
Groheux, David [5 ,6 ,7 ]
Cook, Gary J. R. [8 ,9 ,10 ,11 ]
Ulaner, Gary A. [12 ,13 ]
Jacene, Heather [14 ,15 ]
Rubio, Isabel T. [16 ]
Schoones, Jan W. [17 ]
Peeters, Marie-Jeanne Vrancken [18 ,19 ]
Poortmans, Philip [20 ,21 ]
Mann, Ritse M. [22 ]
Graff, Stephanie L. [23 ,24 ]
Dibble, Elizabeth H. [25 ]
de Geus-Oei, Lioe-Fee [2 ,26 ,27 ]
机构：
[1] Champalimaud Fdn, Champalimaud Clin Ctr, Nucl Med Radiopharmacol, Lisbon, Portugal
[2] Leiden Univ Med Ctr, Dept Radiol, Leiden, Netherlands
[3] Clin Delgado AUNA, PET CT Dept, Lima, Peru
[4] Champalimaud Fdn, Champalimaud Clin Ctr, Breast Unit, Lisbon, Portugal
[5] St Louis Hosp, Nucl Med Dept, Paris, France
[6] Univ Paris Diderot, INSERM U976, Paris, France
[7] Ctr Imagerie Radioisotop CIRI, La Rochelle, France
[8] Kings Coll London, Dept Canc Imaging, London, England
[9] Kings Coll London, London, England
[10] Guys & St Thomas PET Ctr, London, England
[11] Kings Coll London, Sch Biomed Engn & Imaging Sci, London, England
[12] Hoag Family Canc Inst, Mol Imaging & Therapy, Newport Beach, CA USA
[13] Univ Southern Calif, Los Angeles, CA USA
[14] Brigham & Womens Hosp, Dana Farber Canc Inst, Boston, MA USA
[15] Harvard Med Sch, Boston, MA USA
[16] Univ Navarra, Clin Univ Navarra, Canc Ctr Clin, Breast Surg Oncol, Madrid, Navarra, Spain
[17] Leiden Univ Med Ctr, Directorate Res Policy, Leiden, Netherlands
[18] Netherlands Canc Inst, Dept Surg Oncol, Amsterdam, Netherlands
[19] Amsterdam Univ Med Ctr, Dept Surg, Amsterdam, Netherlands
[20] Iridium Netwerk, Dept Radiat Oncol, Antwerp, Belgium
[21] Univ Antwerp, Antwerp, Belgium
[22] RadboudUMC, Radiol Dept, Nijmegen, Netherlands
[23] Lifespan Canc Inst, Providence, RI USA
[24] Brown Univ, Legorreta Canc Ctr, Providence, RI USA
[25] Brown Univ, Dept Diagnost Imaging, Warren Alpert Med Sch, Providence, RI 02912 USA
[26] Univ Twente, Biomed Photon Imaging Grp, Enschede, Netherlands
[27] Delft Univ Technol, Dept Radiat Sci & Technol, Delft, Netherlands
来源：
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING | 2024年 / 51卷 / 09期
关键词：
2-[F-18]FDG; Breast cancer; No special type; PET/CT; EANM; SNMMI; EMISSION TOMOGRAPHY/COMPUTED TOMOGRAPHY; WHOLE-BODY MRI; PATHOLOGICAL COMPLETE RESPONSE; NEOADJUVANT SYSTEMIC THERAPY; CLINICAL-PRACTICE GUIDELINES; STANDARDIZED UPTAKE VALUES; CONTRAST-ENHANCED CT; F-18; FDG-PET/CT; BONE METASTASES; COMPUTED-TOMOGRAPHY;
D O I：
10.1007/s00259-024-06696-9
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
Introduction There is much literature about the role of 2-[F-18]FDG PET/CT in patients with breast cancer (BC). However, there exists no international guideline with involvement of the nuclear medicine societies about this subject. Purpose To provide an organized, international, state-of-the-art, and multidisciplinary guideline, led by experts of two nuclear medicine societies (EANM and SNMMI) and representation of important societies in the field of BC (ACR, ESSO, ESTRO, EUSOBI/ESR, and EUSOMA). Methods Literature review and expert discussion were performed with the aim of collecting updated information regarding the role of 2-[F-18]FDG PET/CT in patients with no special type (NST) BC and summarizing its indications according to scientific evidence. Recommendations were scored according to the National Institute for Health and Care Excellence (NICE) criteria. Results Quantitative PET features (SUV, MTV, TLG) are valuable prognostic parameters. In baseline staging, 2-[F-18]FDG PET/CT plays a role from stage IIB through stage IV. When assessing response to therapy, 2-[F-18]FDG PET/CT should be performed on certified scanners, and reported either according to PERCIST, EORTC PET, or EANM immunotherapy response criteria, as appropriate. 2-[F-18]FDG PET/CT may be useful to assess early metabolic response, particularly in non-metastatic triple-negative and HER2+ tumours. 2-[F-18]FDG PET/CT is useful to detect the site and extent of recurrence when conventional imaging methods are equivocal and when there is clinical and/or laboratorial suspicion of relapse. Recent developments are promising. Conclusion 2-[F-18]FDG PET/CT is extremely useful in BC management, as supported by extensive evidence of its utility compared to other imaging modalities in several clinical scenarios.
引用
收藏
页码：2706 / 2732
页数：27
相关论文
共 240 条
  • [51] PET-based estradiol challenge as a predictive biomarker of response to endocrine therapy in women with estrogen-receptor-positive breast cancer
    Dehdashti, Farrokh
    Mortimer, Joanne E.
    Trinkaus, Kathryn
    Naughton, Michael J.
    Ellis, Matthew
    Katzenellenbogen, John A.
    Welch, Michael J.
    Siegel, Barry A.
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 2009, 113 (03) : 509 - 517
  • [52] Delbeke D, 2006, J NUCL MED, V47, P885
  • [53] EANM guideline on the role of 2-[18F]FDG PET/CT in diagnosis, staging, prognostic value, therapy assessment and restaging of ovarian cancer, endorsed by the American College of Nuclear Medicine (ACNM), the Society of Nuclear Medicine and Molecular Imaging (SNMMI) and the International Atomic Energy Agency (IAEA)
    Delgado Bolton, Roberto C.
    Aide, Nicolas
    Colletti, Patrick M.
    Ferrero, Annamaria
    Paez, Diana
    Skanjeti, Andrea
    Giammarile, Francesco
    [J]. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2021, 48 (10) : 3286 - 3302
  • [54] Pattern of metastatic spread in triple-negative breast cancer
    Dent, Rebecca
    Hanna, Wedad M.
    Trudeau, Maureen
    Rawlinson, Ellen
    Sun, Ping
    Narod, Steven A.
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 2009, 115 (02) : 423 - 428
  • [55] Strategies and technical challenges for imaging oligometastatic disease: Recommendations from the European Organisation for Research and Treatment of Cancer imaging group
    deSouza, Nandita M.
    Liu, Yan
    Chiti, Arturo
    Oprea-Lager, Daniela
    Gebhart, Geraldine
    Van Beers, Bernard E.
    Herrmann, Ken
    Lecouvet, Frederic E.
    [J]. EUROPEAN JOURNAL OF CANCER, 2018, 91 : 153 - 163
  • [56] The prognostic value of SUVmax measuring on primary lesion and ALN by 18F-FDG PET or PET/CT in patients with breast cancer
    Diao, Wei
    Tian, Fangfang
    Jia, Zhiyun
    [J]. EUROPEAN JOURNAL OF RADIOLOGY, 2018, 105 : 1 - 7
  • [57] Biodistribution of 89Zr-trastuzumab and PET Imaging of HER2-Positive Lesions in Patients With Metastatic Breast Cancer
    Dijkers, E. C.
    Munnink, T. H. Oude
    Kosterink, J. G.
    Brouwers, A. H.
    Jager, P. L.
    de Jong, J. R.
    van Dongen, G. A.
    Schroder, C. P.
    Lub-de Hooge, M. N.
    de Vries, E. G.
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2010, 87 (05) : 586 - 592
  • [58] Spectrum of the Breast Lesions With Increased 18F-FDG Uptake on PET/CT
    Dong, Aisheng
    Wang, Yang
    Lu, Jianping
    Zuo, Changjing
    [J]. CLINICAL NUCLEAR MEDICINE, 2016, 41 (07) : 543 - 557
  • [59] Assessment of residual tumour by FDG-PET: conventional imaging and clinical examination following primary chemotherapy of large and locally advanced breast cancer
    Dose-Schwarz, J.
    Tiling, R.
    Avril-Sassen, S.
    Mahner, S.
    Lebeau, A.
    Weber, C.
    Schwaiger, M.
    Jaenicke, F.
    Untch, M.
    Avril, N.
    [J]. BRITISH JOURNAL OF CANCER, 2010, 102 (01) : 35 - 41
  • [60] Fusion of metabolic function and morphology:: Sequential [18F] fluorodeoxyglucose positron-emission tomography/computed tomography studies yield new insights into the natural history of bone metastases in breast cancer
    Du, Yong
    Cullum, Ian
    Illidge, Tim M.
    Ell, Peter J.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (23) : 3440 - 3447
12345678910